Advances in the research of HIV-1 envelope glycoprotein gp120 inhibitors
10.16438/j.0513-4870.2022-1063
- VernacularTitle:HIV-1包膜糖蛋白gp120小分子抑制剂的研究进展
- Author:
Ming-hui XIE
;
Zhao WANG
;
Yan-ying SUN
;
Xiang-yi JIANG
;
Peng ZHAN
;
Xin-yong LIU
;
Dong-wei KANG
- Publication Type:Research Article
- Keywords:
human immunodeficiency virus-1;
entry inhibitor;
gp120;
BMS-626529;
NBD-14270
- From:
Acta Pharmaceutica Sinica
2023;58(3):616-628
- CountryChina
- Language:Chinese
-
Abstract:
From the process of human immunodeficiency virus-1 (HIV-1) invading cells, the combination of gp120 and CD4 is the first step for HIV-1 to invade cells. Interfering with this process can prevent HIV from recognizing target cells and inhibit virus replication. Therefore, HIV-1 gp120 is an important part of the HIV-1 life cycle. Fostesavir, a phosphatate prodrug derived from the gp120 inhibitor BMS-626529 modified by the prodrug strategy, was approved for the treatment of adult patients with multidrug resistant HIV-1 infection by the US FDA and the European Medicines Agency in 2020 and 2021, respectively. In this review, we focus on the research progress of small molecule inhibitors targeting the interaction of gp120-CD4 from the perspective of medicinal chemistry, in order to provide reference for the subsequent research of gp120 inhibitors.
